Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab
Executive Summary
Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.
You may also be interested in...
Lumakras Sales A Highlight Of Amgen’s Mixed Q3
While revenue beat consensus, the company slightly lowered its 2021 guidance due to pandemic impacts, but the closely watched KRAS G12C inhibitor exceeded expectations in its first full quarter.
First Lumakras Combo Data Show Boosted Efficacy For Amgen Drug In CRC
Amgen’s KRAS G12C inhibitor in combination with the company’s Vectibix generated a 27% overall response rate, nearly tripling the responses seen with Lumakras monotherapy in colorectal cancer.
Lumakras A Big Focus For Amgen; More Data Coming Soon
Amgen reported 5% year-over-year revenue growth to $6.5bn in the second quarter, up 11% from Q1. It did not break out Lumakras sales but detailed upcoming data that may support future indications.